Stocks Flirt With All-Time Highs on Earnings, Deals News
NEW YORK (TheStreet) -- U.S. stocks climbed Tuesday amid pharmaceutical deals headlines and better-than-expected existing-home sales.
Netflix (NFLX) was popping after its quarterly earnings call, contributing to sharp gains in the Nasdaq.
The Dow Jones Industrial Average closed up 0.4% to 16,514.37, the S&P 500 added 0.51% to 1,879.55 and the Nasdaq rose 0.97% to 4,161.46.
- In deal news, Novartis (NVS), GlaxoSmithKline (GSK) and Eli Lilly (LLY) have entered into a multibillion-dollar deal. Novartis shares increased 1.3% and GlaxoSmithKline jumped 4.1%. Eli Lilly was drifting lower.
- Allergan (AGN - Get Report) soared 15.3% and Valeant Pharmaceuticals (VRX - Get Report) advanced 7.5% on news that Valeant is seeking to buy Allergan for an estimated $45 billion.
- Existing-home sales for March fell 0.2% to a seasonally adjusted annual pace of 4.59 million, vs. the expected 4.55 million. The Federal Housing Finance Agency House Price Index rose 0.6% in February, up from a downwardly revised 0.4% the prior month.
- Netflix spiked 7% after announcing earnings of 86 cents a share, 3 cents higher than estimates, and $1.27 billion in revenue. The streaming giant also said it plans to raise prices by $1 or $2 per month to fund its library expansion.
- Comcast (CMCSA) earned 68 cents a share, 4 cents higher than estimates as the Sochi Olympics broadcasts boosted the bottom line. Shares popped 1.9%.
- European markets moved higher, boosted by M&A movement in the pharmaceutical sector. London's FTSE moved 0.85% higher, Germany's DAX was up 2.02%, and France's CAC 40 gained 1.18%.
- Japan's Nikkei closed 0.85% lower to 14,388.77 as Japanese companies prepare to report earnings and issue guidance for the fiscal year ending March 2015.
- On Monday, U.S. stock indices closed modestly higher, with the S&P 500 booking a five-day winning streak.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts